Compare Armata Pharmaceuticals, Inc. with Similar Stocks
Stock DNA
Pharmaceuticals & Biotechnology
USD 353 Million (Micro Cap)
NA (Loss Making)
NA
0.00%
-1.42
50.21%
-3.69
Revenue and Profits:
Net Sales:
1 Million
(Quarterly Results - Sep 2025)
Net Profit:
-27 Million
Total Returns (Price + Dividend) 
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
55.37%
0%
55.37%
6 Months
181.54%
0%
181.54%
1 Year
309.27%
0%
309.27%
2 Years
143.9%
0%
143.9%
3 Years
341.58%
0%
341.58%
4 Years
58.0%
0%
58.0%
5 Years
53.66%
0%
53.66%
Armata Pharmaceuticals, Inc. for the last several years.
Risk Adjusted Returns v/s 
News
No Recent News for the Company
Announcements 
No announcement available
Corporate Actions 
No corporate action available
Quality key factors 
Factor
Value
Sales Growth (5y)
41.79%
EBIT Growth (5y)
-25.42%
EBIT to Interest (avg)
-20.19
Debt to EBITDA (avg)
Negative Net Debt
Net Debt to Equity (avg)
-1.78
Sales to Capital Employed (avg)
0.08
Tax Ratio
0
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
2.28%
ROCE (avg)
0
ROE (avg)
0
Valuation key factors
Factor
Value
P/E Ratio
NA (Loss Making)
Industry P/E
Price to Book Value
-3.69
EV to EBIT
-14.66
EV to EBITDA
-15.35
EV to Capital Employed
12.07
EV to Sales
96.73
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
-82.34%
ROE (Latest)
Negative BV
Technicals key factors
Indicator
Weekly
Monthly
MACD
Bullish
Bullish
RSI
No Signal
No Signal
Bollinger Bands
Mildly Bullish
Mildly Bullish
Moving Averages
Mildly Bullish (Daily)
KST
Mildly Bearish
Bullish
Dow Theory
Mildly Bullish
No Trend
OBV
Mildly Bearish
No Trend
Shareholding Snapshot : Sep 2025
Shareholding Compare (%holding) 
Majority shareholders
Domestic Funds
Domestic Funds
Held in 4 Schemes (1.16%)
Foreign Institutions
Held by 5 Foreign Institutions (0.02%)
Strategic Entities with highest holding
Highest Public shareholder
Quarterly Results Snapshot (Consolidated) - Sep'25 - QoQ
Sep'25
Jun'25
Change(%)
Net Sales
1.20
2.20
-45.45%
Operating Profit (PBDIT) excl Other Income
-7.40
-6.50
-13.85%
Interest
4.30
3.80
13.16%
Exceptional Items
-14.60
-5.80
-151.72%
Consolidate Net Profit
-26.70
-16.30
-63.80%
Operating Profit Margin (Excl OI)
-6,709.20%
-3,155.40%
-355.38%
USD in Million.
Net Sales
QoQ Growth in quarter ended Sep 2025 is -45.45% vs 340.00% in Jun 2025
Consolidated Net Profit
QoQ Growth in quarter ended Sep 2025 is -63.80% vs -150.77% in Jun 2025
Annual Results Snapshot (Consolidated) - Dec'24
Dec'24
Dec'23
Change(%)
Net Sales
5.20
4.50
15.56%
Operating Profit (PBDIT) excl Other Income
-41.10
-39.90
-3.01%
Interest
10.70
2.60
311.54%
Exceptional Items
33.60
-25.70
230.74%
Consolidate Net Profit
-18.90
-69.00
72.61%
Operating Profit Margin (Excl OI)
-8,201.80%
-9,028.50%
82.67%
USD in Million.
Net Sales
YoY Growth in year ended Dec 2024 is 15.56% vs -18.18% in Dec 2023
Consolidated Net Profit
YoY Growth in year ended Dec 2024 is 72.61% vs -86.99% in Dec 2023
About Armata Pharmaceuticals, Inc. 
Armata Pharmaceuticals, Inc.
Pharmaceuticals & Biotechnology
Armata Pharmaceuticals, Inc., formerly AmpliPhi Biosciences Corporation, is a biotechnology company. The Company is focused on the discovery, development and commercialization of phage therapeutics. The Company is engaged in identifying, characterizing and developing naturally occurring bacteriophages with its collaboration partners in bacteriophage biology, synthetic biology and manufacturing, to develop second-generation bacteriophage products. The Company is engaged in developing these phage product candidates using a discovery and development platform, which is designed for identification, characterization and manufacturing of multiple phage therapies. Each product candidate combines several chosen phages, which target a specific disease-causing bacterial pathogen, such as staphylococcus aureus (S. aureus), Pseudomonas aeruginosa (P. aeruginosa) and clostridium difficile (C. difficile). Its product candidates are AB-SA01 and AB-PA01.
Company Coordinates 
Company Details
4503 Glencoe Ave , MARINA DEL REY CA : 90292-6372
Registrar Details






